seca mBCA的個性化癌症管理

最新 06-25

For oncological patients, their nutritional condition and their body composition are the most important parameters used in their treatment.Recent studies over the past few years have focused intensely on these parameters and their influence on the risk of cancer, cancer prognosis and its treatment. Generally, obesity is considered to be an important risk factor in the development of a large number of tumors - but it"s the type of fat distribution that seems to be related to the development of cancer. While hypodermic fat has little influence on the progression of certain tumors,studies have shown that an increased amount of intra-abdominal or visceral fat tissue acts as an accelerator and may even worsen the overall prognosis.

對於腫瘤患者來說，他們的營養狀況和身體成分是治療中最重要的參數。最近幾年的研究集中在這些參數及其對癌症風險、癌症預後和治療的影響上。一般來說，肥胖被認為是大量腫瘤發生的重要危險因素，但脂肪分布的類型似乎與癌症的發生有關。儘管皮下脂肪對某些腫瘤的進展影響不大，但研究表明，腹腔內或內臟脂肪組織數量的增加起到了加速作用，甚至可能惡化整體預後。

On the other hand, an unclear weight loss serves as an important symptom, which may occur before a proper diagnosis. In addition, many patients develop malnutrition, sarcopenia or tumor cachexia because of the disease, or as side effects of therapy. This unclear weight loss can have a negative effect on the overall therapy and prognosis, and can increase mortality or reduce a patient"s quality of life to a great extent.

另一方面，不清楚的體重減輕是一個重要癥狀，這可能發生在正確診斷之前。此外，許多患者因疾病或因治療出現的副作用而出現營養不良、少肌症或腫瘤惡病質。這種不清楚的體重減輕會對整體治療和預後產生負面影響，並在很大程度上增加死亡率或降低患者的生活質量。

Due to insufficient energy and nutrient uptake, malnutrition leads to loss of weight, muscle and fat tissue. Sarcopenia, on the other hand, is an age-dependent, excessive loss of muscle mass and strength, which is not necessarily associated with weight loss. This way, a patient may develop sarcopenic obesity, where their muscle mass decreases, while their fat tissue notably increases. In contrast to malnutrition and sarcopenia, cachexia develops mainly in the context of chronic or tumorous diseases. In addition to weight loss, combined with excessive catabolization of fat and muscle mass,cachexia is accompanied by acute or chronic inflammation.

由於能量和營養攝入不足，營養不良導致體重、肌肉和脂肪組織減少。另一方面，肌肉減少症是一種年齡依賴性的肌肉質量和力量的過度喪失，這不一定與體重減輕有關。這樣，患者可能會出現肌肉減少性肥胖，肌肉質量減少，而脂肪組織明顯增加。與營養不良和少肌症不同，惡病質主要發生在慢性或腫瘤性疾病中。惡病質除了體重減輕，再加上脂肪和肌肉過度分解，還伴有急性或慢性炎症。

Due to the different pathomechanisms, therapeutic approaches andcourses, the distinction between these three conditions plays an importantrole. Malnutrition and sarcopenia are completely or partially reversible, ifthey are diagnosed early and treated accordingly. The aforementionedconditions illustrate the relevance of the nutritional condition and the bodycomposition for oncological patients. Until now, computer and magneticresonance tomography were considered the gold standard for the evaluation of apatient"s body composition. Ourseca mBCAoffers an alternative to these expensive and complex procedures,with its bioimpedance analysis (BIA). Clinical trials compared theseca mBCAwith the respective standards,validating its use in research or in general clinical settings. In just a fewseconds, theseca mBCAnon-invasively measures individual body compartments and easilydetects minor changes in a patient"s body composition. In addition, it providesaccurate information on the hydration state and the localization of fat andmuscle mass in a patient"s body.

由於發病機制、治療方法和病程不同，這三種情況的區別起著重要作用。營養不良和少肌症是完全或部分可逆的，如果它們被早期診斷並得到相應的治療。上述情況說明了腫瘤患者營養狀況和身體成分的相關性。迄今為止，計算機和磁共振斷層成像被認為是評估患者身體成分的金標準。我們的seca mBCA以其生物阻抗分析( BIA )為這些昂貴而複雜的程序提供了一種替代方案。臨床試驗將seca mBCA與相應的標準進行比較，驗證其在研究或一般臨床環境中的應用。在短短几秒鐘內，seca mBCA非侵入性地測量單個身體隔室，並且容易檢測患者身體成分的微小變化。此外，它還提供了關於患者體內脂肪和肌肉質量的水合狀態和定位的準確信息。

In the future, the close control of a patient"s body compositionand their dietary condition will gain further importance in the field ofoncology. Within the scope of personalized cancer management, a patient"scancer therapy can be adapted based on their current constitution, thusincreasing the treatment"s effectiveness and reducing the occurrence of side effects. Withourseca mBCA,a BIA device is already available, which meets all these requirements and caneffectively help improve the treatment, prognosis and quality of life ofoncologic patients.

今後，密切控制患者的身體成分和飲食狀況將在腫瘤學領域變得更加重要。在個性化癌症管理的範圍內，患者的癌症治療可以根據其目前的體質進行調整，從而提高治療效果，減少副作用的發生。藉助seca mBCA，BIA設備已經具備，能夠滿足所有這些要求，並能有效幫助改善腫瘤患者的治療、預後和生活質量。